logo True scholar network
Back to Top
Visit Website

Leukemia & Lymphoma (L&L)

Publisher :

Taylor & Francis

Scopus Profile
Peer reviewed only
Scopus Profile
Open Access
  • Leukemia & Lymphoma
  • disease biology
  • ethics and epidemiology

    • +5

e-ISSN :

1029-2403

Issue Frequency :

Monthly

Impact Factor :

2.2

p-ISSN :

1042-8194

Est. Year :

1989

Mobile :

4402080520500

DOI :

YES

Country :

United Kingdom

Language :

English

APC :

YES

Impact Factor Assignee :

GOOGLE SCHOLAR

Email :

apol@cc.huji.ac.il

Journal Descriptions

Leukemia & Lymphoma is an international peer reviewed journal that publishes research on all aspects of hematological malignancies. The journal aims to address the needs of physicians and scientists interested in clinical, translational, laboratory and basic science research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders. Leukemia & Lymphoma covers from clinical and clinico-pathological investigations to fundamental research in the following topics: disease biology mechanisms of action of novel agents development of combination chemotherapy pharmacology and pharmacogenomics ethics and epidemiology


Leukemia & Lymphoma (L&L) is :

International, Peer-Reviewed, Open Access, Refereed, Leukemia & Lymphoma, disease biology, ethics and epidemiology, pharmacology and pharmacogenomics, mechanisms of action of novel agents, unique clinical observations, review articles, letters to the editor , Online or Print, Monthly Journal

UGC Approved, ISSN Approved: P-ISSN - 1042-8194, E-ISSN - 1029-2403, Established in - 1989, Impact Factor - 2.2

Provide Crossref DOI

Indexed in Scopus, WoS

Not indexed in DOAJ, PubMed, UGC CARE

Indexing

Scopus Profile
Scopus
Scopus Profile
WoS
Scopus Profile
Crossref

+1 More

Publications of L&L

  • dott image April, 2025

Glofitamab results in cost savings versus epcoritamab in relapsed/refractory diffuse large B-cell lymphoma: a total cost of care analysisFootnote‡

Fixed-treatment duration glofitamab and treat-to-progression epcoritamab are approved in the US for diffuse large B-cell lymphoma (DLBCL) after ≥2 prior therapies. An economic model was de...

  • dott image April, 2025

Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma

Relapsed refractory primary central nervous system lymphoma (R/R PCNSL) has no recognized optimal therapy due to its grave prognosis and high mortality. This report describes a 69-year-old p...

  • dott image March, 2025

The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis

Symptoms of lymphomas include peripheral lymphadenopathy, B-symptoms, and other organ-specific symptoms; however, data on initial symptoms incidence in diffuse large B-cell lymphoma (DLBCL) ...

  • dott image March, 2025

Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation

In acute myeloid leukemia with NPM1 mutation, analysis of measurable residual disease (MRD) with reverse transcription quantitative polymerase chain reaction (RT-qPCR) is recommended for res...

  • dott image May, 2025

Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymp...

This study described real-world treatment patterns and outcomes among patients with CLL/SLL in the post-cBTKi setting. Included were patients who received at least one cBTKi and subsequent l...

  • dott image March, 2025

Allogeneic stem cell transplantation for MDS—clinical issues, choosing preparative regimens and outcome

Despite the vast heterogeneity of myelodysplastic neoplasm (MDS), treatment options are limited and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curativ...

  • dott image March, 2025

CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors

Chronic myeloid leukemia (CML) is a hematopoietic stem cell malignancy, driven by the pathognomonic oncogenic fusion protein BCR::ABL1. Tyrosine kinase inhibitors (TKIs) targeting ABL1 have ...

  • dott image February, 2025

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-c...

In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH]...

  • dott image February, 2025

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia...

Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leuke...

  • dott image January, 2025

Indolent lymphoma: addressing the needs of survivors

Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectan...

Establish Your Own Journal Without the Expense!

OJSCloud offers a complete, free setup to get you publishing.

Start Your Free Journal!
free profile